Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334

Next Previous
Trial Profile

An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen

    • Most Recent Events

    • 14 Jun 2023 Results of sub-group analysis assessing long-term efficacy and safety of erenumab in patients with chronic migraine with acute medication overuse, published in the Headache.
    • 01 May 2022 Results of subgroup analysis and post hoc analysis assessing long-term efficacy and safety of erenumab in group of patients with chronic migraine in whom prior preventive treatments had failed and never failed, published in the Headache
    • 20 Dec 2021 Results of post-hoc secondary analysis of NCT01952574, NCT02456740, NCT02483585, NCT02066415, and NCT02174861 assessing the efficacy and safety profiles of erenumab in patients with migraine with aura, published in the JAMA Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top